A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

David R. Martinez^{1,7}, Alexandra Schaefer^{1,7}, Sophie Gobeil^{2,7}, Dapeng Li^{2,7}, Gabriela De la Cruz³, Robert Parks², Xiaozhi Lu², Maggie Barr², Kartik Manne², Katayoun Mansouri², Robert J. Edwards², Boyd Yount¹, Kara Anasti², Stephanie A. Montgomery⁴, Shaunna Shen⁶, Tongqing Zhou⁵, Peter D. Kwong⁵, Barney S. Graham⁵, John R. Mascola⁵, David. C. Montefiori⁶, Munir Alam², Gregory D. Sempowski², Kevin Wiehe², Kevin O. Saunders^{2,6}, Priyamvada Acharya^{2,6,*}, Barton F. Haynes^{2,*}, Ralph S. Baric^{1,*}.

¹ Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

² Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA

³ Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA

⁴ Department of Laboratory Medicine and Pathology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

⁵ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA

⁶ Department of Surgery, Duke University School of Medicine, Durham, NC, USA

⁷ These authors contributed equally.

*Corresponding authors.

Priyamvada Acharya, P.A., priyamvada.acharya@duke.edu

Barton F. Haynes, B.F.H., barton.haynes@duke.edu

Ralph S. Baric, R.S.B., rbaric@email.unc.edu

Keywords: SARS-CoV-2 D614G, B.1.1.7, B.1.429, B.1.351, SARS-like virus, *Sarbecovirus*, countermeasures, DH1047 antibody, bNAb, panCoV

Abstract

SARS-CoV in 2003, SARS-CoV-2 in 2019, and SARS-CoV-2 variants of concern (VOC) can cause deadly infections, underlining the importance of developing broadly effective countermeasures against Group 2B Sarbecoviruses, which could be key in the rapid prevention and mitigation of future zoonotic events. Here, we demonstrate the neutralization of SARS-CoV, bat CoVs WIV-1 and RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, B.1.429, B.1.351 by a receptor-binding domain (RBD)-specific antibody DH1047. Prophylactic and therapeutic treatment with DH1047 demonstrated protection against SARS-CoV, WIV-1, RsSHC014, and SARS-CoV-2 B.1.351 infection in mice. Binding and structural analysis showed high affinity binding of DH1047 to an epitope that is highly conserved among Sarbecoviruses. We conclude that DH1047 is a broadly neutralizing and protective antibody that can prevent infection and mitigate outbreaks caused by SARS-like strains and SARS-CoV-2 variants. Our results argue that the RBD conserved epitope bound by DH1047 is a rational target for pan Group 2B coronavirus vaccines.

Introduction

The emergence of severe acute respiratory syndrome (SARS-CoV) in 2003 led to more than 8,000 infections and 800 deaths^{1,2}. In 2012, the Middle East Respiratory Syndrome (MERS-CoV) emerged in Saudi Arabia³, which has so far infected ~2,600 people and caused 900 deaths. Less than a decade following the emergence of MERS-CoV, SARS-CoV-2 emerged in Wuhan, China⁴. The spread of SARS-CoV-2, the virus that causes coronavirus disease of 2019 (COVID-19) was rapid, and by March 2020, the World Health Organization (WHO) had declared SARS-CoV-2 a global pandemic. By April 2021, more than 140 million people had been infected globally, resulting in >3 million deaths. Therefore, there is a need to develop safe and effective broad-spectrum countermeasures that can prevent the rapid spread and attenuate the severe disease outcomes associated with current and future SARS-like virus emergence events.

Human highly pathogenic CoV outbreaks are likely of bat origin⁵, and there is great genetic diversity among bat SARS-like viruses⁶. Zoonotic CoVs of bat origin, such as RsSHC014 and WIV-1, can utilize the human ACE2 receptor for cell entry and infect human airway cells^{7,8}, underlining their potential for emergence in naïve human populations. Moreover, existing SARS-CoV therapeutic monoclonal antibodies and SARS-CoV-2 mRNA vaccines do not protect against zoonotic SARS-like virus infection⁷⁻⁹. Given the pandemic potential of SARS-like viruses, the development of broadly effective countermeasures, such as universal vaccination strategies⁹⁻¹¹, and coronavirus (CoV) cross-reactive monoclonal antibodies is a global health priority. Moreover, given the emergence of the SARS-CoV-2 variants that are partially or fully resistant to some neutralizing antibodies authorized for COVID-19 treatment¹²⁻¹⁴, there is a need to discover mAb therapies that are broadly effective against the SARS-CoV-2 variants and zoonotic SARS-like viruses that will continue to emerge in the future.

The receptor binding domain (RBD) of SARS-CoV-2 is one of the targets for highly potent neutralizing antibodies. Despite the high degree of genetic diversity within the RBD in SARS-like viruses⁶, antibodies can be engineered to recognize diverse SARS-like viruses. Rappazzo *et al.* recently reported that an engineered RBD-directed antibody, ADG-2, neutralized SARS-like viruses and protected against SARS-CoV and wild type SARS-CoV-2¹⁵. Therefore, the RBD of Sarbecoviruses contains conserved epitopes that are the target of broadly neutralizing antibodies. In agreement with the notion that the RBD contains a conserved epitope shared among SARS, SARS-like, SARS-CoV-2 and the variants, we have identified a panCoV protective antibody: DH1047. Here, we demonstrate, using both pseudoviruses and live virus assays, that DH1047 neutralizes SARS-CoV, SARS-like bat viruses RsSHC014 and WIV-1, and SARS-CoV-2 D614G, B.1.1.7, B.1.429, B.1.351 variants. Structural analysis shows that DH1047 targets a highly conserved RBD region among the Sarbecoviruses. Importantly, we also demonstrate that DH1047 provides prophylactic and therapeutic protection activity against pathogenic SARS-CoV, RsSHC014, WIV-1, wild type SARS-CoV-2, and against a pathogenic B.1.351 variant in mice. Thus, DH1047 is a pan-group 2B CoV protective antibody that can be used to prevent and treat SARS-CoV-2 infections including important with variants of concern and has the potential to prevent disease from a future outbreak of a pre-emergent, zoonotic SARS-like virus strains that jump into naïve animal and human populations.

Results

The identification of broadly cross-binding and neutralizing antibodies

We previously isolated 1737 monoclonal antibodies (mAbs) from a SARS-CoV convalescent patient 17 years following infection and a SARS-CoV-2 convalescent patient from

36 days post infection¹⁶. From this large panel of mAbs previously described by Li *et al.* we focused on 50 cross-reactive antibodies which bound to SARS-CoV, SARS-CoV-2, and other human and animal CoV antigens¹⁶. To examine if these cross-reactive mAbs neutralized divergent Sarbecoviruses, we measured neutralizing activity against a mouse-adapted SARS-CoV-2 2AA mouse-adapted (MA) virus, SARS-CoV, bat CoV WIV-1, and bat CoV RsSHC014 using live viruses, and found four broadly cross-reactive antibodies, DH1235, DH1073, DH1046, and DH1047 (Fig. 1). DH1235 neutralized SARS-CoV-2 2AA MA, SARS-CoV, and bat CoV WIV-1 with IC₅₀ of 0.122, 0.0403, and 0.060 µg/ml, respectively (Fig. 1A and Table S1). DH1073 neutralized SARS-CoV-2 2AA MA, SARS-CoV, and bat CoV WIV-1 with IC₅₀ of 0.808, 0.016, and 0.267 µg/ml, respectively (Fig. 1B and Table S1). DH1046 neutralized SARS-CoV-2 2AA MA, SARS-CoV, bat CoV WIV-1, and bat CoV RsSHC014 with IC₅₀ of 2.85, 0.103, 0.425, and 1.27 µg/ml, respectively (Fig. 1C and Table S1). Similar to DH1046, DH1047 more potently neutralized SARS-CoV-2 2AA MA, SARS-CoV, bat CoV WIV-1, and bat CoV RsSHC014 with IC₅₀ of 0.397, 0.028, 0.191, and 0.200 µg/ml, respectively (Fig. 1D and Table S1).

We also measured binding responses for DH1235, DH1073, DH1046, and DH1047 against zoonotic bat RaTG13-CoV, bat RsSHC014, and Pangolin GXP4L-CoV spikes. DH1235, DH1073, DH1046, and DH1047 mAbs showed strong binding to bat RaTG13-CoV, bat RsSHC014, and pangolin GXP4L-CoV spikes in addition to SARS-CoV and SARS-CoV-2 (Fig. 1E-1H). Finally, DH1235, DH1073, DH1046, and DH1047 bound to SARS-CoV-2 RBD and did not bind to the SARS-CoV-2 NTD, demonstrating specific binding to the RBD. While DH1235, DH1073, DH1046, and DH1047 were cross-reactive against epidemic, pandemic, and zoonotic Sarbecovirus spikes, they did not bind to MERS-CoV, HuCoV OC43, HuCoV NL63, and

HuCoV 229E spike proteins (Fig. S1), suggesting these mAbs recognize a conserved epitope found only in Group 2B betacoronaviruses. By Negative Stain Electron Microscopy (NSEM), we observed binding of DH1047 to the RBD of bat RsSHC014 and SARS-CoV spike ectodomains, with overall similar orientations as was observed for DH1047 binding to the SARS-CoV-2 spike ectodomain (Figure S2)¹⁶.

Finally, DH1235, DH1073, DH1046, and DH1047 exhibited medium to long heavy-chain-complementarity-determining-region 3 (HCDR3) lengths and variable somatic mutation rates in the heavy chain genes. DH1235, DH1073, and DH1046, had HCDR3 lengths of 21, 15, and 24, and somatic hypermutation (SMH) rates of 1.7, 9.0, and 4.7, respectively (Table S2). The most potent neutralizing antibody DH1047 had HCDR3 lengths and SMH rates of 24 and 8.05, respectively (Table S2).

The protective activity of DH1235, DH1073, DH1046, and DH1047 against SARS-CoV

To define the protective efficacy of these four RBD-specific IgG bNAbs, we passively immunized aged mice with DH1235, DH1073, DH1046, DH1047 and a negative control influenza mAb, CH65¹⁷, at 10mg/kg 12 hours prior to infection and evaluated lung viral titer replication. Neither DH1235, DH1073, nor DH1046 protected against SARS-CoV mouse-adapted passage 15 (MA15) challenge in mice and all had lung viral replication comparable to that of control mice (Fig. 2A). In contrast, prophylactic administration of DH1047 fully protected mice from lung viral titer replication (Fig. 2A). Given the prophylactic potential of DH1047, we sought to also evaluate its therapeutic potential in a highly sensitive and stringent aged mouse model. We treated mice with control mAb and DH1047 at 10mg/kg both at 12 hours before and 12 hours post infection with SARS-CoV MA15 and monitored mice for signs of clinical disease,

including weight loss, pulmonary function, which was measured by whole-body plethysmography (Buxco), through day 4 post infection (d4pi). In agreement with the SARS-CoV MA15 experiments, prophylactic treatment with DH1047 protected mice from weight loss through d4pi (Fig. 2B), and also protected mice from lung viral replication (Fig. 2C). We also evaluated if the prophylactic and therapeutic administration of DH1047 protected against lung pathology as measured by 1) lung discoloration, which is a visual metric of gross lung damage taken at the time of the necropsy, 2) microscopic evaluation as measured by an acute lung injury (ALI) scheme, and 3) a diffuse alveolar damage (DAD) scheme. ALI and DAD, which are characterized by histopathologic changes including alveolar septal thickening, protein exudate in the airspace, hyaline membrane formation, and neutrophils in the interstitium or alveolar sacs, were both blindly evaluated by a board-certified veterinary pathologist. The prophylactic administration of DH1047 resulted in complete protection from macroscopic lung discoloration (Fig. 2D) and microscopic lung pathology as measured by ALI (Fig. 2E and Fig. S3) and DAD (Fig. 2F and Fig. S3). Similarly, the therapeutic administration of DH1047 12 hours post infection resulted in reductions in lung viral titers (Fig. 2C and Fig. S3) as well as the macroscopic lung damage measured by the lung discoloration score (Fig. 2D and Fig. S3). In contrast to the prophylactic treatment condition, therapeutic administration of DH1047 did not significantly reduce microscopic lung pathology compared to control mice as measured by ALI (Fig. 2E and Fig. S3) and DAD (Fig. 2F and Fig. S3) in this highly susceptible model for SARS-CoV pathogenesis. Thus, DH1047 can prevent SARS-CoV disease when administered prophylactically and has early measurable therapeutic benefits in highly susceptible aged mouse models, much like other SARS-CoV-2 therapeutic neutralizing antibodies which have the most benefit in outpatient settings^{4,18,19}.

Cryo-EM structure of the SARS-CoV/DH1047 complex

To visualize the binding epitope of DH1047 and to compare with the previously reported structure of the complex with the SARS-CoV-2 spike ectodomain¹⁶, we solved the cryo-EM structure of SARS-CoV bound to DH1047. 3D-classification of the cryo-EM dataset resulted in a 3.20 Å resolution reconstruction showing three DH1047 Fab bound to each of the 3 RBD of the ectodomain in the “up” position (1 Fab:1 RBD ratio) (Fig. 3, Figure S5 and Table S3). Similar to what we had observed for the DH1047 complex with the SARS-CoV-2 spike ectodomain¹⁶, there was considerable heterogeneity in the RBD region; further classification of particles was performed to better resolve the antibody binding interface, resulting in an asymmetric reconstruction of a population refined to a resolution of 3.4 Å that was used for model fitting. The angle of approach and footprint of DH1047 on the SARS-CoV RBD closely resembled that in the SARS-CoV-2 complex with steric overlap predicted with ACE2 binding (Figure 3A-C). These results demonstrate that DH1047 binds to SARS-CoV and SARS-CoV-2 spike ectodomains by involving homologous interactions, consistent with our analysis of RBD sequence variability that showed a high degree of convergence of the DH1047 epitope¹⁰, thereby defining an RBD conserved site of vulnerability among Sarbecoviruses. The DH1047 epitope on the SARS-CoV-2 RBD is distinct from other known antibodies of Classes 1, 2, 3 and 4 (Figure 3D). The DH1047 epitope overlays with that of antibody ADG-2, yet the two epitopes are distinct, and related by a rotation about the Fab longitudinal axis that pivots the ADG-2 antibody more towards the ACE2 binding region (Figures 3D and S6). Finally, we defined the binding affinity of DH1047 against epidemic and zoonotic spike proteins. We measured binding on and off rates against both SARS-CoV and RsSHC014-CoV spike proteins via surface plasmon

resonance (SPR). DH1047 bound to the SARS-CoV and RsSCH014-CoV spikes with high affinity, association rates ($> 8.60 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$) and dissociation rates ($< 1.0 \times 10^{-5} \text{ s}^{-1}$) (Fig. S4), demonstrating that DH1047 binds tightly to both the epidemic SARS-CoV and pre-emergent bat CoVs that are poised for human emergence.

The prophylactic and therapeutic activity of DH1047 against bat pre-emergent CoVs and *in vitro* neutralization activity against the SARS-CoV-2 variants

As DH1047 neutralized both the pre-emergent bat CoVs WIV-1 and RsSHC014 (Fig. 1), we sought to define if DH1047 had prophylactic and therapeutic efficacy in mice. We evaluated the protective efficacy against lung viral replication against these pre-emergent bat CoVs. We administered DH1047 prophylactically 12 hours before infection and therapeutically 12 hours post infection at 10mg/kg in mice infected with bat CoVs. Importantly, the prophylactic administration of DH1047 completely protected mice from WIV-1 lung viral replication and reduced lung viral titers in therapeutically treated mice compared to control mice (Fig. 4A). Similarly, the prophylactic administration of DH1047 completely protected mice from RsSHC014 lung viral replication and significantly reduced viral replication to near undetectable levels in therapeutically treated mice (Fig. 4B). While we previously demonstrated the prophylactic and therapeutic efficacy of DH1047 against the wild type SARS-CoV-2 in cynomolgus macaques¹⁶, which exhibit mild SARS-CoV-2 disease²⁰, it was not known if the mutations present in the newly emerging SARS-CoV-2 variants would ablate the neutralizing activity of DH1047. We therefore evaluated if DH1047 could neutralize the prevalent variants of concern (VOCs): SARS-CoV-2 D614G, SARS-CoV-2 UK B.1.1.7., SARS-CoV-2 California B1.429, and SARS-CoV South Africa B1.351 using both pseudovirus and live virus

neutralization assays. DH1047 neutralized all tested variants of concern with substantial potency (Fig. 4C and Fig. 4D). Pseudovirus neutralization assays revealed strong neutralization of DH1047 against the SARS-CoV-2 VOCs (Fig. 4D). Importantly, live virus neutralization also demonstrated the broadly neutralizing activity of DH1047 with IC₅₀ values against D614G, B.1.1.7, and B.1.351 were 0.059, 0.081, and 0.111 µg/ml, respectively.

The prophylactic and therapeutic activity of DH1047 against SARS-CoV-2 B.1.351 in mice

Given that the B.1.351 South African variant is more resistant to both vaccine-elicited neutralizing antibodies^{14,21}, and completely ablates the neutralizing activity of the Eli Lilly therapeutic monoclonal antibody LY-CoV555¹², we also sought to evaluate if DH1047 had both prophylactic and therapeutic efficacy against SARS-CoV-2 B.1.351, which incorporates the B.1.351 spike in the SARS-CoV MA10 genome backbone²². We again utilized a highly susceptible and vulnerable aged mouse model in the SARS-CoV-2 B.1.351 protection experiments. Consistent with the SARS-CoV, WIV-1, and RsSHC014 *in vivo* data, the prophylactic administration of DH1047 mediated protection against severe weight loss following SARS-CoV-2 B.1.351 challenge in aged mice (Fig. 5A). In contrast, we did not observe differences in weight loss from the therapeutic administration of DH1047 (Fig. 5A). Mice prophylactically treated with DH1047 had undetectable levels of SARS-CoV-2 B.1.351 lung viral replication (Fig. 5B) and were also completely protected from macroscopic lung pathology compared to controls (Fig. 5C). While we observed no significant protection from weight loss in DH1047 therapeutically treated mice, we did observe a significant reduction in lung viral titers compared to control (Fig. 5B). We also evaluated the microscopic lung pathology as measured by ALI (Fig. 5D) and DAD scoring schemes (Fig. 5E) in this highly susceptible aged model for

SARS-CoV-2 B.1.351 pathogenesis. Importantly, the prophylactic administration of DH1047 significantly protected mice from lung histopathology as measured by ALI and DAD compared to control mice. Additionally, we observed a reduction in ALI by the therapeutic administration of DH1047 as measure by macroscopic lung pathology (Fig. 5C) and lung histopathology by ALI (Fig. 5D). Therefore, DH1047 can prevent and treat SARS-CoV-2 infections with the B.1.351 variant of concern *in vivo*, especially if given early in infection.

Discussion

The emergence of SARS-CoV and SARS-CoV-2 in the last two decades underscores a critical need to develop broadly effective countermeasures against Sarbecoviruses. Moreover, with the recent emergence of more highly transmissible²³, virulent²⁴, and neutralization resistant UK B.1.1.7 variant, that can partially evade existing countermeasures^{12,14}, there is a need to develop next-generation mAb therapeutics that can broadly neutralize these variants, as well as future variants of concern. For example, the SARS-CoV-2 South African B.1.351 variant completely ablates the neutralization activity of the mAb LY-CoV555^{12,13}. As a result, the emergency use authorization (EUA) of LY-CoV555 was recently rescinded by the U.S. Food and Drug Administration (FDA). In addition, the presence of the E484K mutation in many variants of concern, severely dampens the neutralization activity by more than 6-fold of the AstraZeneca COV2-2196 mAb, Bii BioSciences mAb Bii-198, and the Regeneron mAb REGN 10933^{13,14,19}. In addition to evading currently monoclonal antibody therapeutics, some of the variants including B.1.351 can diminish the efficacy of clinically approved vaccines, including the Johnson & Johnson single-dose vaccine and the AstraZeneca ChAdOx1^{25,26}. Furthermore, some monoclonal antibodies isolated from vaccine recipients of the Moderna and Pfizer vaccines also

demonstrated reduced efficacy against mutations present in the variants²⁷. Therefore, current vaccine and mAb therapies must be monitored in real time to define the performance of existing therapies against newly emerging and spreading variants. In the setting of reduced vaccine efficacy, the deployment of effective mAb therapies against the variants, such as DH1047, could be a strategy to help control the COVID-19 pandemic.

The development of universal vaccination strategies against Sarbecoviruses will be improved by the identification and characterization of broadly protective and conserved epitopes across SARS-like virus strains. Recent studies described broadly reactive antibodies that target the subunit 2 (S2) portion of the spike protein²⁸⁻³¹. While the broad recognition of these S2-specific antibodies is encouraging, these antibodies weakly neutralized diverse CoVs. Given the limited characterization of these mAbs, it is unclear if these S2-specific mAbs are broadly protective *in vivo* against diverse epidemic and zoonotic pre-emergent CoVs. In contrast, RBD-specific antibody, S2X259, neutralized SARS-CoV-2 variants and zoonotic SARS-like viruses, as measured by pseudovirus neutralization³². Similarly, a recent subset of RBD-specific cross-reactive mAbs also showed *in vitro* activity³³, although their *in vivo* breadth and protective efficacy remains unconfirmed. It is interesting that DH1235, DH1073, and DH1046 neutralized SARS-CoV but did not protect against SARS-CoV challenge *in vivo*. Perhaps DH1235, DH1073, and DH1046 require 1) non-neutralizing functions for protecting against infection *in vivo*, or 2) have a distinct mode or angle of binding to SARS-CoV compared to DH1047 required for the observed protection. This underlines the importance of performing *in vivo* protection studies in addition to *in vitro* neutralization assays to truly define the protective efficacy of panCoV-specific mAbs.

In contrast to ADG-2 which uses VH3-21 for its heavy chain and has a 17 amino acid long HCDR3, DH1047 uses VH1-46 and has a 24 amino acid long HCDR3 (Table S2)¹⁵. Moreover, ADG-2 and DH1047 have overlapping, yet distinct binding footprints, targeting a conserved region on the RBD (Fig. S6). In addition, the DH1047 epitope is distinct to those from cross-reactive antibodies S309 and CR3022 (Fig. 3D) and targets an epitope near those from class 4 antibodies. DH1047 had broad protective *in vivo* efficacy against pre-emergent SARS-like viruses, epidemic SARS-CoV, and the SARS-CoV-2 B.1.351 variant, underscoring that DH1047 recognizes a pan Sarbecovirus neutralizing epitope. Consistent with this notion, we have described a SARS-CoV-2 RBD-ferritin nanoparticle vaccine that elicited neutralizing antibodies against pre-emergent SARS-like viruses and protected against SARS-CoV-2 challenge in monkeys¹⁰. The serum antibody responses in these SARS-CoV-2 RBD-ferritin nanoparticle-vaccinated monkeys could block DH1047 binding responses against SARS-CoV-2 spike proteins, suggesting that SARS-CoV-2 RBD vaccines elicit DH1047-like antibody responses and could potentially protect against the future emergence of SARS- or SARS2-like viruses.

Moving forward, it will be critical to closely monitor SARS- and SARS2-like viruses of zoonotic origin and actively monitor if broad-spectrum antibodies like ADG-2, DH1047, and S2X259 retain their inhibitory activity against pre-emergent viruses. We envision a system in which broad-spectrum antibodies like DH1047 could be tested for safety in small Phase I clinical trials so that in the event that a future SARS-like virus emerges, DH1047 could immediately be tested in larger efficacy trials at the site of an outbreak to potentially prevent the rapid spread of an emergent CoV. Moreover, given that DH1047 exhibited strong *in vivo* protection against the SARS-CoV-2 B.1.351 VOC, this mAb could be deployed as a mAb therapeutic to help control

the current COVID-19 pandemic. Like other therapeutic antibodies evaluated against COVID19 infections, our data argues that early administration will prove critical for protecting against severe disease outcomes ¹⁹. We conclude that DH1047 is a broadly protective mAb that has efficacy against pre-emergent, zoonotic SARS-like viruses from different clades, neutralizes highly transmissible SARS-CoV-2 variants, and protects against SARS-CoV-2 B.1.351.

321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340

Methods

Antibody isolation

Antibodies were isolated from antigen-specific single B cells as previously described from an individual who had recovered from SARS-CoV-1 infection 17 years prior to leukapheresis, and from a SARS-CoV-2 convalescent individual from 36 days post infection ¹⁶.

Measurement of CoV spike binding by ELISA

Indirect binding ELISAs were conducted in 384 well ELISA plates (Costar #3700) coated with 2µg/ml antigen in 0.1M sodium bicarbonate overnight at 4°C, washed and blocked with assay diluent (1XPBS containing 4% (w/v) whey protein/ 15% Normal Goat Serum/ 0.5% Tween-20/ 0.05% Sodium Azide). mAbs were incubated for 60 minutes in three-fold serial dilutions beginning at 100µg/ml followed by washing with PBS/0.1% Tween-20. HRP conjugated goat anti-mouse IgG secondary antibody (SouthernBiotech 1030-05) was diluted to 1:10,000 in assay diluent without azide, incubated at for 1 hour at room temperature, washed and detected with 20µl SureBlue Reserve (KPL 53-00-03) for 15 minutes. Reactions were stopped via the addition of 20µl HCL stop solution. Plates were read at 450nm. Area under the curve (AUC) measurements were determined from binding of serial dilutions.

Measurement of neutralizing antibodies against live viruses

Full-length SARS-CoV-2 Seattle, SARS-CoV-2 D614G, SARS-CoV-2 B.1.351, SARS-CoV-2 B.1.1.7, SARS-CoV, WIV-1, and RsSHC014 viruses were designed to express

nanoluciferase (nLuc) and were recovered via reverse genetics as described previously¹⁶. Virus titers were measured in Vero E6 USAMRIID cells, as defined by plaque forming units (PFU) per ml, in a 6-well plate format in quadruplicate biological replicates for accuracy. For the 96-well neutralization assay, Vero E6 USAMRID cells were plated at 20,000 cells per well the day prior in clear bottom black walled plates. Cells were inspected to ensure confluency on the day of assay. mAbs were serially diluted 3-fold up to nine dilution spots at specified concentrations. Serially diluted mAbs were mixed in equal volume with diluted virus. Antibody-virus and virus only mixtures were then incubated at 37°C with 5% CO₂ for one hour. Following incubation, serially diluted mAbs and virus only controls were added in duplicate to the cells at 75 PFU at 37°C with 5% CO₂. After 24 hours, cells were lysed, and luciferase activity was measured via Nano-Glo Luciferase Assay System (Promega) according to the manufacturer specifications. Luminescence was measured by a Spectramax M3 plate reader (Molecular Devices, San Jose, CA). Virus neutralization titers were defined as the sample dilution at which a 50% reduction in RLU was observed relative to the average of the virus control wells.

Surface plasmon resonance

Kinetic measurements of the DH1047 Fab binding to SARS-CoV and RsSHC014 spike proteins were obtained using a Biacore S200 instrument (Cytiva, formerly GE Healthcare) in HBS-EP+ 1X running buffer. The spike proteins were first captured onto a Series S Streptavidin chip to a level of 300-400 for the SARS-CoV spike proteins and 850-1000RU for the RsSHC014 spike protein. The DH1047 Fab was diluted from 2.5 to 200nM and injected over the captured CoV spike proteins using the single cycle kinetics injection type at a flow rate of 50µL/min. There were five 120s injections of the Fab at increasing concentrations followed by a

dissociation of 600s after the final injection. After dissociation, the spike proteins were regenerated from the streptavidin surface using a 30s pulse of Glycine pH1.5. Results were analyzed using the Biacore S200 Evaluation software (Cytiva). A blank streptavidin surface along with blank buffer binding were used for double reference subtraction to account for non-specific protein binding and signal drift. Subsequent curve fitting analyses were performed using a 1:1 Langmuir model with a local Rmax for the DH1047 Fab. The reported binding curves are representative of 2 data sets.

Protein expression and purification for EM studies

The SARS-CoV spike ectodomain construct comprised the residues 1 to 1190 (UniProt P59594-1) with proline substitutions at 968-969, a C-terminal T4 fibrin trimerization motif, a C-terminal HRV3C protease cleavage site, a TwinStrepTag and an 8XHisTag. The construct was cloned into the mammalian expression vector p α H³⁴. The RsSHC014 spike ectodomain construct was prepared similarly, except it also contained the 2P mutations that placed two consecutive proline at the HR1-CH junction at residue positions 986 and 987. FreeStyle 293F cells were used for the spike ectodomain production. Cells were maintained in FreeStyle 293 Expression Medium (Gibco) at 37°C and 9% CO₂, with agitation at 120 rpm in a 75% humidified atmosphere. Transfections were performed as previously described³⁵⁻³⁸ using Turbo293 (SpeedBiosystems). 16 to 18 hours post transfection, HyClone CDM4HEK293 media (Cytiva, MA) was added. On the 6th day post transfection, spike ectodomain was harvested from the concentrated supernatant. The purification was performed using StrepTactin resin (IBA LifeSciences) and size exclusion chromatography (SEC) on a Superose 6 10/300 GL Increase column (Cytiva, MA) in 2mM Tris, pH 8.0, 200 mM NaCl, 0.02% NaN₃. All steps were

performed at room temperature and the purified spike proteins were concentrated to 1-5 mg/ml, flash frozen in liquid nitrogen and stored at -80 °C until further use.

DH1047 IgG was produced in Expi293F cells maintained in Expi293 Expression Medium (Gibco) at 37°C, 120 rpm, 8% CO₂ and 75% humidity. Plasmids were transfected using the ExpiFectamine 293 Transfection Kit and protocol (Gibco)³⁵⁻³⁷ and purified by Protein A affinity. The IgG was digested to the Fab state using LysC.

Negative Stain Electron Microscopy (NSEM)

NSEM was performed as described previously¹⁶. Briefly, Fab-spike complexes were prepared by mixing Fab and spike to give a 9:1 molar ratio of Fab to spike. Following a 1-hr incubation for 1 hour at 37 °C, the complex was cross-linked by diluting to a final spike concentration of 0.1 mg/ml into room-temperature buffer containing 150 mM NaCl, 20 mM HEPES pH 7.4, 5% glycerol, and 7.5 mM glutaraldehyde and incubating for 5 minutes. Excess glutaraldehyde was quenched by adding sufficient 1 M Tris pH 7.4 stock to give a final concentration of 75 mM Tris and incubated for 5 minutes. Carbon-coated grids (EMS, CF300-cu-UL) were glow-discharged for 20s at 15 mA, after which a 5-μl drop of quenched sample was incubated on the grid for 10-15 s, blotted, and then stained with 2% uranyl formate. After air drying grids were imaged with a Philips EM420 electron microscope operated at 120 kV, at 82,000x magnification and images captured with a 2k x 2k CCD camera at a pixel size of 4.02 Å.

The RELION 3.0 program was used for all negative stain image processing. Images were imported, CTF-corrected with CTFFIND, and particles were picked using a spike template from previous 2D class averages of spike alone. Extracted particle stacks were subjected to 2-3 rounds of 2D class averaging and selection to discard junk particles and background picks. Cleaned

particle stacks were then subjected to 3D classification using a starting model created from a bare spike model, PDB 6vsb, low-pass filtered to 30 Å. Classes that showed clearly defined Fabs were selected for final refinements followed by automatic filtering and B-factor sharpening with the default Relion post-processing parameters.

Cryo-EM

Purified SARS-CoV-1 spike ectodomain was incubated for approximately 2 hours with a 6-fold molar equivalent of the DH1047 Fab in a final volume of 10µL. The sample concentration was adjusted to ~1.5 mg/mL of spike in 2 mM Tris pH 8.0, 200 mM NaCl, and 0.02% NaN₃. Before freezing, 0.1µL of glycerol was added to the 10µL of sample. A 2.4-µL drop of protein was deposited on a Quantifoil-1.2/1.3 grid (Electron Microscopy Sciences, PA) that had been glow discharged for 10 seconds using a PELCO easiGlow™ Glow Discharge Cleaning System. After a 30-second incubation in >95% humidity, excess protein was blotted away for 2.5 seconds before being plunge frozen into liquid ethane using a Leica EM GP2 plunge freezer (Leica Microsystems). Frozen grids were imaged using a Titan Krios (Thermo Fisher) equipped with a K3 detector (Gatan). Data processing was performed using cryoSPARC³⁹. Model building and refinement was done using Phenix^{40,41}, Coot⁴², Pymol⁴³, Chimera⁴⁴, ChimeraX⁴⁵ and Isolde⁴⁶.

Animals and challenge viruses

Eleven-month-old female BALB/c mice were purchased from Envigo (#047) and were used for the SARS-CoV, SARS-CoV-2 B.1.351, and RsSHC014-CoV protection experiments. 8-10-week-old hACE2-transgenic mice were bred at UNC Chapel Hill and were used for WIV-1-

CoV protection experiments. The study was carried out in accordance with the recommendations for care and use of animals by the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health and the Institutional Animal Care and Use Committee (IACUC) of University of North Carolina (UNC permit no. A-3410-01). Animals were housed in groups of five and fed standard chow diets. Virus inoculations were performed under anesthesia and all efforts were made to minimize animal suffering. All mice were anesthetized and infected intranasally with 1×10^4 PFU/ml of SARS-CoV MA15, 1×10^4 PFU/ml of SARS-CoV-2 B1.351-MA10, 1×10^4 PFU/ml RsSHC014, 1×10^4 PFU/ml WIV-1, which have been described previously^{7,22,47}. Mice were weighted daily and monitored for signs of clinical disease, and selected groups were subjected to daily whole-body plethysmography. For all mouse studies, groups of n=10 mice were included per arm of the study except for the hACE2-transgenic mice, which included n=5 mice per group due to a limited availability of these mice. Viral titers, weight loss, and histology were measured from individual mice per group.

Lung pathology scoring

Acute lung injury was quantified via two separate lung pathology scoring scales: Matute-Bello and Diffuse Alveolar Damage (DAD) scoring systems. Analyses and scoring were performed by a board verified veterinary pathologist who was blinded to the treatment groups as described previously⁴⁸. Lung pathology slides were read and scored at 600X total magnification.

The lung injury scoring system used is from the American Thoracic Society (Matute-Bello) in order to help quantitate histological features of ALI observed in mouse models to relate this injury to human settings. In a blinded manner, three random fields of lung tissue were chosen and scored for the following: (A) neutrophils in the alveolar space (none = 0, 1–5 cells =

1, > 5 cells = 2), (B) neutrophils in the interstitial septa (none = 0, 1–5 cells = 1, > 5 cells = 2),
 (C) hyaline membranes (none = 0, one membrane = 1, > 1 membrane = 2), (D) Proteinaceous
 debris in air spaces (none = 0, one instance = 1, > 1 instance = 2), (E) alveolar septal thickening
 (< 2x mock thickness = 0, 2–4x mock thickness = 1, > 4x mock thickness = 2). To obtain a lung
 injury score per field, A–E scores were put into the following formula score = [(20x A) + (14 x
 B) + (7 x C) + (7 x D) + (2 x E)]/100. This formula contains multipliers that assign varying
 levels of importance for each phenotype of the disease state. The scores for the three fields per
 mouse were averaged to obtain a final score ranging from 0 to and including 1. The second
 histology scoring scale to quantify acute lung injury was adopted from a lung pathology scoring
 system from lung RSV infection in mice⁴⁹. This lung histology scoring scale measures diffuse
 alveolar damage (DAD). Similar to the implementation of the ATS histology scoring scale, three
 random fields of lung tissue were scored for the following in a blinded manner: 1= absence of
 cellular sloughing and necrosis, 2=Uncommon solitary cell sloughing and necrosis (1–2
 foci/field), 3=multifocal (3+foci) cellular sloughing and necrosis with uncommon septal wall
 hyalinization, or 4=multifocal (>75% of field) cellular sloughing and necrosis with common
 and/or prominent hyaline membranes. The scores for the three fields per mouse were averaged to
 get a final DAD score per mouse. The microscope images were generated using an Olympus
 Bx43 light microscope and CellSense Entry v3.1 software.

Biocontainment and biosafety

Studies were approved by the UNC Institutional Biosafety Committee approved by
 animal and experimental protocols in the Baric laboratory. All work described here was
 performed with approved standard operating procedures for SARS-CoV-2 in a biosafety level 3

(BSL-3) facility conforming to requirements recommended in the Microbiological and Biomedical Laboratories, by the U.S. Department of Health and Human Service, the U.S. Public Health Service, and the U.S. Center for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH).

Statistics

All statistical analyses were performed using GraphPad Prism 9.

Data availability

Structural data of DH1047 will be made available after publication.

Code availability

No code was generated in this study.

ACKNOWLEDGEMENTS

Funding: David R. Martinez is currently supported by a Burroughs Wellcome Fund Postdoctoral Enrichment Program Award and a Hanna H. Gray Fellowship from the Howard Hughes Medical Institute and was supported by an NIH NIAID T32 AI007151 and an NIAID F32 AI152296.

This research was also supported by funding from the Chan Zuckerberg Initiative awarded to R.S.B. This project was supported by the North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly. This project was funded in part by the National Institute of Allergy and Infectious Diseases, NIH, U.S. Department of

505 Health and Human Services award AI157155 (R.S.B), U54 CA260543 (R.S.B), AI149644
506 (R.S.B), AI145687 (P.A.), as well as an animal models contract from the NIH
507 (HHSN272201700036I). Funding was also supplied by the Intramural Research Program of the
508 Vaccine Research Center, NIAID, NIH. This work was supported by a grant from the State of
509 North Carolina with funds from the federal CARES Act, and by funds from NIH, NIAID,
510 DAIDS grant AI142596 (B.F.H). Animal histopathology services were performed by the Animal
511 Histopathology & Laboratory Medicine Core at the University of North Carolina, which is
512 supported in part by an NCI Center Core Support Grant (5P30CA016086-41) to the UNC
513 Lineberger Comprehensive Cancer Center. Part of this work was performed in the Duke
514 Regional Biocontainment Laboratory, which received partial support for construction from the
515 NIH/NIAID (UC6AI058607; G.D.S) and with support from a cooperative agreement with
516 DOD/DARPA (HR0011-17-2-0069; G.D.S). This project was also supported by the North
517 Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill and Duke
518 University with funding from the North Carolina Coronavirus Relief Fund established and
519 appropriated by the North Carolina General Assembly. Cryo-EM data were collected on the
520 Titan Krios system at the Shared Materials and Instrumentation Facility in Duke University. We
521 thank Nilakshee Bhattacharya and Mark Walters for microscope alignments and assistance with
522 cryo-EM data collection. This study utilized the computational resources offered by Duke
523 Research Computing (<http://rc.duke.edu>; NIH 1S10OD018164-01) at Duke University. We thank
524 C. Kneifel, M. Newton, V. Orlikowski, T. Milledge, and D. Lane from the Duke Office of
525 Information Technology and Research Computing for assisting with setting up and maintaining
526 the computing environment. We thank A. Foulger, N. Jamieson, J. Kittrell, E. Lee, and A.
527 Sanzone for DNA and antibody production.

528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550

Author contributions: Conceived the study: D.R.M., A.S., S.G., D.L., P.A., B.F.H., R.S.B. designed experiments: D.R.M., A.S., S.G., D.L., performed laboratory experiments: D.R.M., A.S., D.L., S.G., Provided critical reagents: T.Z., P.D.K., B.S.G., and K.O.S. Analyzed data and provided critical insight: D.R.M., A.S., S.G., D.L., G.D.L.C., R.P., M.B., K.M., B.Y., K.A., S.M., T.Z., P.D.K., B.S.G., J.R.M., D.C.M., M.A., G.D.S., K.W., K.O.S., P.A., B.F.H., R.S.B.; Wrote the first draft of the paper: D.R.M.; Read and edited the paper: D.R.M., A.S., S.G., D.L., T.Z., P.D.K., B.S.G., J.R.M., D.C.M., M.A., G.D.S., K.W., K.O.S., P.A., B.F.H., R.S.B. Funding acquisition: D.R.M., G.D.S., B.F.H., R.S.B. All authors reviewed and approved the manuscript.

Competing interests: Duke University has filed provisional patents for which B.F.H., K.O.S., D.L., and G.D.S., are inventors on a provisional U.S. patent for mAb DH1047 and its applications described in this study.

551

552 REFERENCES

- 553 1. Peiris, J.S., *et al.* Coronavirus as a possible cause of severe acute respiratory syndrome.
554 *Lancet* **361**, 1319-1325 (2003).
- 555 2. Cherry, J.D. & Krogstad, P. SARS: The First Pandemic of the 21st Century. *Pediatric*
556 *Research* **56**, 1-5 (2004).
- 557 3. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D. & Fouchier, R.A.
558 Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J*
559 *Med* **367**, 1814-1820 (2012).
- 560 4. Zhou, P., *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat
561 origin. *Nature* **579**, 270-273 (2020).
- 562 5. Li, W., *et al.* Bats Are Natural Reservoirs of SARS-Like Coronaviruses. *Science* **310**,
563 676-679 (2005).
- 564 6. Hu, B., *et al.* Discovery of a rich gene pool of bat SARS-related coronaviruses provides
565 new insights into the origin of SARS coronavirus. *PLoS Pathog* **13**, e1006698 (2017).
- 566 7. Menachery, V.D., *et al.* A SARS-like cluster of circulating bat coronaviruses shows
567 potential for human emergence. *Nat Med* **21**, 1508-1513 (2015).
- 568 8. Menachery, V.D., *et al.* SARS-like WIV1-CoV poised for human emergence. *Proc Natl*
569 *Acad Sci U S A* **113**, 3048-3053 (2016).
- 570 9. Martinez, D.R., *et al.* Chimeric spike mRNA vaccines protect against sarbecovirus
571 challenge in mice. *bioRxiv*, 2021.2003.2011.434872 (2021).
- 572 10. Saunders, K.O., *et al.* SARS-CoV-2 vaccination induces neutralizing antibodies against
573 pandemic and pre-emergent SARS-related coronaviruses in monkeys. *bioRxiv* (2021).
- 574 11. Walls, A.C., *et al.* Elicitation of broadly protective sarbecovirus immunity by receptor-
575 binding domain nanoparticle vaccines. *bioRxiv* (2021).
- 576 12. Wang, L., *et al.* Antibodies with potent and broad neutralizing activity against
577 antigenically diverse and highly transmissible SARS-CoV-2 variants. *bioRxiv* (2021).
- 578 13. Wang, P., *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
579 *Nature* (2021).
- 580 14. Chen, R.E., *et al.* Resistance of SARS-CoV-2 variants to neutralization by monoclonal
581 and serum-derived polyclonal antibodies. *Nat Med* (2021).
- 582 15. Rappazzo, C.G., *et al.* Broad and potent activity against SARS-like viruses by an
583 engineered human monoclonal antibody. *Science* **371**, 823-829 (2021).
- 584 16. Li, D., *et al.* The functions of SARS-CoV-2 neutralizing and infection-enhancing
585 antibodies in vitro and in mice and nonhuman primates. *bioRxiv* (2021).
- 586 17. Whittle, J.R., *et al.* Broadly neutralizing human antibody that recognizes the receptor-
587 binding pocket of influenza virus hemagglutinin. *Proc Natl Acad Sci U S A* **108**, 14216-
588 14221 (2011).
- 589 18. An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19. *JAMA* (2020).
- 590 19. Martinez, D.R., *et al.* Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in
591 mice. *bioRxiv*, 2021.2001.2027.428478 (2021).
- 592 20. Leist, S.R., Schäfer, A. & Martinez, D.R. Cell and animal models of SARS-CoV-2
593 pathogenesis and immunity. *Dis Model Mech* **13**(2020).

- 594 21. Planas, D., *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to
595 neutralizing antibodies. *Nature Medicine* (2021).
- 596 22. Leist, S.R., *et al.* A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and
597 Mortality in Standard Laboratory Mice. *Cell* **183**, 1070-1085.e1012 (2020).
- 598 23. Davies, N.G., *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage
599 B.1.1.7 in England. *Science* **372**, eabg3055 (2021).
- 600 24. Davies, N.G., *et al.* Increased mortality in community-tested cases of SARS-CoV-2
601 lineage B.1.1.7. *Nature* (2021).
- 602 25. Sadoff, J., *et al.* Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against
603 Covid-19. *New England Journal of Medicine* (2021).
- 604 26. Madhi, S.A., *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the
605 B.1.351 Variant. *New England Journal of Medicine* (2021).
- 606 27. Wang, Z., *et al.* mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating
607 variants. *Nature* (2021).
- 608 28. Wang, C., *et al.* A conserved immunogenic and vulnerable site on the coronavirus spike
609 protein delineated by cross-reactive monoclonal antibodies. *Nature Communications* **12**,
610 1715 (2021).
- 611 29. Zhou, P., *et al.* A protective broadly cross-reactive human antibody defines a conserved
612 site of vulnerability on beta-coronavirus spikes. *bioRxiv* (2021).
- 613 30. Sauer, M.M., *et al.* Structural basis for broad coronavirus neutralization. *bioRxiv* (2020).
- 614 31. Jennewein, M.F., *et al.* Isolation and Characterization of Cross-Neutralizing Coronavirus
615 Antibodies from COVID-19+ Subjects. *bioRxiv* (2021).
- 616 32. Tortorici, M.A., *et al.* Structural basis for broad sarbecovirus neutralization by a human
617 monoclonal antibody. *bioRxiv* (2021).
- 618 33. Jette, C.A., *et al.* Broad cross-reactivity across sarbecoviruses exhibited by a subset of
619 COVID-19 donor-derived neutralizing antibodies. *bioRxiv*, 2021.2004.2023.441195
620 (2021).
- 621 34. Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
622 conformation. *Science* **367**, 1260-1263 (2020).
- 623 35. Henderson, R., *et al.* Controlling the SARS-CoV-2 spike glycoprotein conformation. *Nat*
624 *Struct Mol Biol* (2020).
- 625 36. Li, D., *et al.* The functions of SARS-CoV-2 neutralizing and infection-enhancing
626 antibodies in vitro and in mice and nonhuman primates. *bioRxiv* (2021).
- 627 37. Acharya, P., *et al.* A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized
628 by Fab-dimerized glycan-reactive antibodies. *bioRxiv* (2020).
- 629 38. Edwards, R.J., *et al.* Cold sensitivity of the SARS-CoV-2 spike ectodomain. *Nature*
630 *Structural & Molecular Biology* **28**, 128-131 (2021).
- 631 39. Punjani, A., Rubinstein, J.L., Fleet, D.J. & Brubaker, M.A. cryoSPARC: algorithms for
632 rapid unsupervised cryo-EM structure determination. *Nature Methods* **14**, 290-296
633 (2017).
- 634 40. Liebschner, D., *et al.* Macromolecular structure determination using X-rays, neutrons and
635 electrons: recent developments in Phenix. *Acta Crystallographica Section D Structural*
636 *Biology* **75**, 861-877 (2019).
- 637 41. Afonine, P.V., *et al.* Real-space refinement in PHENIX for cryo-EM and crystallography.
638 *Acta Crystallographica Section D Structural Biology* **74**, 531-544 (2018).

42. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development ofCoot. *Acta Crystallographica Section D Biological Crystallography* **66**, 486-501 (2010).
43. Schrodinger, L. The PyMOL Molecular Graphics System. (2015).
44. Pettersen, E.F., *et al.* UCSF Chimera?A visualization system for exploratory research and analysis. *Journal of Computational Chemistry* **25**, 1605-1612 (2004).
45. Goddard, T.D., *et al.* UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Science* **27**, 14-25 (2018).
46. Croll, T.I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta Crystallogr D Struct Biol* **74**, 519-530 (2018).
47. Roberts, A., *et al.* A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. *PLoS Pathog* **3**, e5 (2007).
48. Sheahan, T.P., *et al.* Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nature Communications* **11**, 222 (2020).
49. Schmidt, M.E., *et al.* Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. *PLoS Pathog* **14**, e1006810 (2018).

Figure legends

Figure 1. The identification of cross-reactive and broadly neutralizing antibodies.

The neutralization activity of four broadly neutralizing antibodies against SARS-CoV-2 2AA mouse-adapted (MA), SARS-CoV, WIV-1, and RsSHC014. SARS-CoV-2 2AA MA is shown in purple, SARS-CoV is shown in orange, WIV-1 is shown in pink, and RsSHC014 is shown in green. The neutralization activity against Sarbecoviruses is shown for (A) DH1235, (B) DH1073, (C) DH1046, and (D) DH1047. The binding activity of cross-reactive antibodies against SARS-CoV spike, SARS-CoV-2 spike, SARS-CoV-2 RBD, Pangolin GXP4L spike, RaTG13 spike, and RsSHC014 spike of (E) DH1235, (F) DH1073, (G) DH1046, and (H) DH1047.

Figure 2: Prevention and therapy of DH1047 against SARS-CoV in aged mice.

(A) SARS-CoV mouse-adapted 15 (MA15) lung viral replication in the prophylactically treated (-12 hours before infection) mice with a control influenza mAb CH65 and the four broadly neutralizing antibodies DH1235, DH1073, DH1046, DH1047.

(B) % Starting weight of prophylactic (-12 hours before infection) and therapeutic (+12 hours after infection) treatment with DH1047 and control against SARS-CoV MA15 in mice.

(C) Lung viral replication of SARS-CoV MA15 in mice treated prophylactically and therapeutically with DH1047 and control at 4 days post infection.

(D) Macroscopic lung discoloration scores in mice treated with DH1047 and control prophylactically and therapeutically.

(E) Lung pathology at day 4 post infection measured by acute lung injury (ALI) scores in mice treated with DH1047 and control prophylactically and therapeutically.

(F) Lung pathology at day 4 post infection measured by diffuse alveolar damage (DAD) in mice treated prophylactically and therapeutically with DH1047 and control.

(G) Pulmonary function as measured by whole body plethysmography (Buxco) in DH1047 and control mAb prophylactically and therapeutically treated mice. P values are from a 2-way ANOVA after Tukey's multiple comparisons test for the weight loss, and P values are from a 1-way ANOVA following Dunnett's multiple comparisons for the viral titer, and lung pathology readouts.

Figure 3. Cryo-EM structure of DH1047 bound to SARS-CoV spike.

(A) Cryo-EM reconstruction of DH1047 Fab bound to SARS-CoV spike shown in grey, with the underlying fitted model shown in cartoon representation. DH1047 is colored green, the RBD it is bound to is colored black with the Receptor Binding Motif within the RBD colored purple.

(B) Overlay of DH1047 bound to SARS-CoV-1 and SARS-CoV-2 (PDB ID: 7LDI) S proteins. Overlay was performed with the respective RBDs. DH1047 bound to SARS-CoV and SARS-CoV-2 spike is shown in green and salmon, respectively.

(C) ACE2 (yellow surface representation, PDB 6VW1) binding to RBD is sterically hindered by DH1047. The views in panels B and C are related by a $\sim 180^\circ$ rotation about the vertical axis.

(D) DH1047 binding relative to binding of other known antibody classes that bind the RBD. RBD is shown in black with the ACE2 footprint on the RBD colored yellow. DH1047 is shown in cartoon representation and colored green. The other antibodies are shown as transparent surfaces: C105 (pale cyan, Class 1, PDB ID: 6XC� and 6XCA), DH1041 (light blue, Class 2,

PDB ID: 7LAA), S309 (wheat, Class 3, PDB ID:6WS6 and 6WPT) and CR3022 (pink, Class 4 ,
PDB ID: 6YLA)

Figure 4: Prophylactic and therapeutic activity of DH1047 against SARS-like bat CoVs and the *in vitro* neutralization against the SARS-CoV-2 variants.

(A) Lung viral replication of WIV-1 in mice treated prophylactically and therapeutically with DH1047 and control at 2 days post infection.

(B) Lung viral replication of RsSHC014 in mice treated prophylactically and therapeutically with DH1047 and control at 2 days post infection.

(C) Live virus neutralization of SARS-CoV-2 D614G, UK B.1.1.7., and South African B.1.351 variants.

(D) The comparison of the DH1047 neutralization activity against the SARS-CoV-2 variants in pseudovirus and live virus neutralization assays. P values are from a 2-way ANOVA after Tukey's multiple comparisons test for the weight loss, and P values are from a 1-way ANOVA following Dunnett's multiple comparisons for the viral titer, and lung pathology readouts.

Figure 5: Prevention and therapy of DH1047 against SARS-CoV-2 B.1.351 in mice.

(A) % Starting weight of prophylactic (-12 hours before infection) and therapeutic (+12 hours after infection) treatment with DH1047 and control against SARS-CoV-2 B.1.351 in mice.

(B) Lung viral replication of SARS-CoV-2 B.1.351 in mice treated prophylactically and therapeutically with DH1047 and control at 4 days post infection.

(C) Macroscopic lung discoloration scores in mice treated with DH1047 and control prophylactically and therapeutically.

(E) Lung pathology at day 4 post infection measured by acute lung injury (ALI) scores in mice treated with DH1047 and control prophylactically and therapeutically.

(F) Lung pathology at day 4 post infection measured by diffuse alveolar damage (DAD) in mice treated prophylactically and therapeutically with DH1047 and control. P values are from a 2-way ANOVA after Tukey's multiple comparisons test for the weight loss, and P values are from a 1-way ANOVA following Dunnett's multiple comparisons for the viral titer, and lung pathology readouts.

Supplemental Figure Legends

Figure S1. The binding activity of cross-reactive antibodies against MERS-CoV and human common-cold CoVs.

The neutralization activity of four broadly neutralizing antibodies against SARS-CoV-2 NTD, MERS-CoV spike, HCoV-OC43 spike, HCoV-NL63, and HCoV-229E shown for (A) DH1235, (B) DH1073, (C) DH1046, and (D) DH1047.

Figure S2. NSEM of DH1047 bound to bat RsSHC014 and SARS-CoV spike ectodomains.

(A) Representative 2D class averages of bat RsSHC014 2P spike ectodomain bound to DH1047 Fab.

(B) Overlay of 3D reconstruction of DH1047 bound to bat RsSHC014 2P (grey) and SARS-CoV-2 HexaPro (purple) S ectodomains.

(C) Representative 2D class averages of SARS-CoV 2P spike ectodomain bound to DH1047 Fab

(D) Overlay of 3D reconstruction of DH1047 bound to bat SARS-CoV 2P (grey) and SARS-CoV-2 HexaPro (purple) S ectodomains. The red boxes in panels A and C indicate the classes that show DH1047 Fab bound to spike.

Figure S3. Lung H+E staining of SARS-CoV infected mice.

Pathologic features of acute lung injury were scored using two separate tools: the American Thoracic Society Lung Injury Scoring (ATS ALI) system. Using this ATS ALI system, we created an aggregate score for the following features: neutrophils in the alveolar and interstitial space, hyaline membranes, proteinaceous debris filling the air spaces, and alveolar septal thickening. Three randomly chosen high power ($\times 60$) fields of diseased lung were assessed per mouse. Representative images are shown from vehicle and RDV-treated mice. All images were taken at the same magnification. The black bar indicates 100 μm scale. (A) CH65 control prophylaxis. (B) CH65 therapy. (C) DH1047 prophylaxis. (D) DH1047 therapy.

Figure S4. The affinity data of DH1047 against SARS-CoV and RsSHC014 spikes.

Surface plasmon resonance (SPR) binding experiments of DH1047 against (A) SARS-CoV-2 Toronto and (B) RsSHC014. Binding affinity measurements are shown in the tables and response

units (RU) as a function of time in seconds (s) is shown for both SARS-CoV and RsSHC014.

SPR experiments were repeated twice.

Figure S5. Cryo-EM data processing for the SARS-CoV spike ectodomain bound to DH1047, Related to Figure 2.

(A) Representative cryo-EM micrograph.

(B) Cryo-EM CTF fit.

(C) Representative 2D class averages from Cryo-EM dataset.

(D) *Ab initio* reconstruction.

(E) Refined map.

(F) Fourier shell correlation curve.

(G) Refined cryo-EM map colored by local resolution.

(H) Zoom-in images showing the SD1, NTD, HR1/CH and RBD/Fab contact regions in the structure. The cryo-EM map is shown as a blue mesh and the fitted model is in cartoon representation, with residues shown as stick.

Figure S6. DH1047 and ADG-2 binds the RBD of SARS-Cov and SARS-CoV-2 spike ectodomains using a similar footprint.

(A) Cartoon representation of DH1047 (colored in pale green) bound to the RBD (grey surface, ACE2 binding site in yellow) of SARS-CoV S ectodomain and ADG-2 (cyan) bound to SARS-CoV-2 S ectodomain. The homologous Fab ADI-19425 (PDB 6APC) was docked in the ADG-2 cryo-EM map (EMD-23160) to generate the model.

803 (B) DH1047 and ADG-2 bind partially overlapping binding sites on the RBD.

804

805 **Supplemental Table 1: monoclonal antibody screen against SARS-CoV-2 2AA MA, SARS-**
806 **CoV, WIV-1, and RsSHC014**

807

808 **Supplemental Table 2: Immunogenetic characteristics of broadly cross-reactive mAbs.**

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

PDB ID		828	Supplementary Table 3.
EMDB ID		829	
Data collection and processing			Cryo-EM data collection and refinements statistics.
Microscope	FEI Titan Krios	830	
Detector	Gatan K3		
Magnification	81,000		
Voltage (kV)	300		
Electron exposure (e ⁻ /Å ²)	54.1		
Defocus range (μm)	~0.75-2.50		
Pixel size (Å)	1.08		
Reconstruction software	cryoSparc		
Symmetry imposed	C1		
Initial particle images (no.)	2,370,616		
Final particle images (no.)	284,619		
Map resolution (Å)	3.43		
FSC threshold	0.143		
Refinement			
Initial model used	7LD1		
Model resolution (Å)	3.43		
FSC threshold	0.143		
Model composition			
Nonhydrogen atoms	28,048		
Protein residues	3,737		
R.m.s. deviations			
Bond lengths (Å)	0.016		
Bond angles (°)	1.956		
Validation			
MolProbity score	1.79		
Clashscore	1.65		
Poor rotamers (%)	2.36		

EM ringer score	2.9	831
Ramachandran plot		
Favored (%)	88.54	832
Allowed (%)	9.79	833
Disallowed (%)	1.66	
<hr/>		834

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure S1

Figure S2

A

B

C

D

Figure S3

A CH65 control -12hr prophylaxis

B CH65 +12hr therapy

C DH1047 -12hr prophylaxis

D DH1047 +12hr therapy

Figure S4

Figure S5

Figure S6

Supplemental Table 1: monoclonal antibody screen against SARS-CoV-2 2AA MA, SARS-CoV, WIV-1, and RsSHC014

mAb #	DH #	mAb	Specificity to SARS-CoV-2	ELISA cross-reactivity	Live virus neutralization IC ₅₀ (µg/ml)			
					SARS-CoV-2 2AA MA	SARS-CoV	WIV-1	RsSHC014
1	DH1058	Ab711725_G1.4A/293i/Citrate	S2	SARS-CoV-1, MERS-CoV, 229E, NL63, HKU1, OC43	>10	>10	>10	>10
2	DH1057	Ab025934_G1.4A/293i/Citrate	S2	SARS-CoV-1, OC43	>10	>10	>10	>10
18	DH1047	Ab712384_LS/293i/Citrate	RBD	SARS-CoV, SARS-CoV-2, and bat CoVs	0.3979	0.0287	0.191	0.2005
45	DH1203	Ab026044_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	3.768	0.04781	>10	>10
46	DH1127	Ab026075_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
47	DH1059	Ab026129L2_LS/293i/Citrate	no binding	SARS-CoV-2	>10	>10	>10	>10
48	DH1081	Ab026147_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
49	DH1085	Ab026160_LS/293i/Citrate	no binding	SARS-CoV-2	>10	>10	>10	>10
50	DH1080	Ab026162_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0059	0.0330	>10
51	DH1061.1	Ab026164_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
52	DH1065	Ab026172_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
53	DH1066	Ab026186_LS/293i/Citrate	NTD	only SARS-CoV	>10	>10	>10	>10
54	DH1064	Ab026188_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0216	>10	>10
55	DH1067	Ab026196_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
56	DH1069	Ab026200_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
57	DH1046	Ab026204_LS/293i/Citrate	RBD	SARS-CoV, SARS-CoV-2, and bat CoVs	2.857	0.1033	0.4248	1.274
58	DH1068	Ab026217_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
59	DH1086	Ab026240_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
60	DH1071	Ab026243_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
61	DH1088	Ab026245_LS/293i/Citrate	no binding	SARS-CoV-2	>10	>10	>10	>10
62	DH1073	Ab026258_LS/293i/Citrate	RBD	SARS-CoV, SARS-CoV-2, and bat CoVs	0.8088	0.0161	0.267	>10
64	DH1235	Ab026319_LS/293i/Citrate	RBD	SARS-CoV, SARS-CoV-2, and bat CoVs	0.1226	0.0403	0.0602	>10
65	#N/A	Ab026336_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
66	DH1193	Ab712053_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	4.345	>10	>10	>10
67	DH1152	Ab712109_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
68	DH1171	Ab712113_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
69	DH1109	Ab712156_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
70	DH1208	Ab712166_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
71	DH1166	Ab712215_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
72	DH1191	Ab712224_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
73	DH1120	Ab712294_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
74	DH1110	Ab712312_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
75	DH1106	Ab712366_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
76	DH1112	Ab712370_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0023	0.1617	>10
77	DH1117	Ab712376_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
78	DH1115	Ab712378_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0083	0.1614	>10
79	DH1093	Ab712381_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
80	DH1095	Ab712402_LS/293i/Citrate	RBD	SARS-CoV	>10	>10	>10	>10
81	DH1113	Ab712404_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
82	DH1114	Ab712407_LS/293i/Citrate	NTD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
84	DH1098	Ab712416_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0052	0.0318	>10
85	DH1101	Ab712423_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0012	>10	>10
86	#N/A	Ab712561_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	0.0399	0.4312	>10
87	#N/A	Ab712572_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
88	#N/A	Ab712584_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
89	#N/A	Ab712585_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
90	#N/A	Ab712588_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
91	#N/A	Ab712614L_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
92	#N/A	Ab712617_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	>10	>10	>10	>10
93	#N/A	Ab712618_LS/293i/Citrate	RBD	SARS-CoV and SARS-CoV-2	9.877	>10	>10	>10

Supplemental Table 2: Immunogenetic characteristics of broadly cross-reactive mAbs

Supplemental Table 01: Immunogenetic characteristics of broadly cross-reactive mAbs													
DH#	Antibody ID	Binding Specificity	Cross Reactivity	Antibody Gene Analysis									
				Donor ID	Time Point	HCDR3 Length	Heavy chain mutation	VH_Gene	JH_Gene	LCDR3 Length	Light chain mutation	VL_Gene	JL_Gene
DH1235	Ab026319_LS	RBD	SARS-CoV-1	SARS-CoV-2 convalescent	Day 36	21	1.68	IGHV3-48	IGHJ4	9	1.75	IGLV4-60	IGLJ2
DH1073	Ab026258_LS	RBD	SARS-CoV-1	SARS-CoV convalescent	Year 17	15	9.06	IGHV1-46	IGHJ6	11	2.92	IGKV3-11	IGKJ1
DH1046	Ab026204_LS	RBD	SARS-CoV, PCoV GXP4L, Bat CoV RsHC014, Bat CoV RaTG13	SARS-CoV convalescent	Year 17	24	4.70	IGHV3-23	IGHJ6	9	3.65	IGKV1-5	IGKJ2
DH1047	Ab712384_LS	RBD	SARS-CoV, PCoV GXP4L, Bat CoV RsHC014, Bat CoV RaTG13	SARS-CoV convalescent	Year 17	24	8.05	IGHV1-46	IGHJ4	9	2.05	IGKV4-3	IGKJ1